poisar

Stocks · News reference

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49

Aug 17, 2026, 4:13 PMBenzinga Newsdesk

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RIGL
Source
benzinga
Observed
Aug 17, 2026, 4:13 PM
Checked
Aug 17, 2026, 4:13 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 13, 2026, 12:13 PMBenzinga Newsdesk

    Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription

    VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to selectively

    Read original at benzinga
    RIGL